MENU

FGEN Stock FibroGen (FGEN, $0.34) Stochastic Oscillator left the overbought zone on December 06, 2024

A.I.dvisor
at Tickeron.com
Loading...
FGEN - FibroGen
Stochastic signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Stochastic signal
Price: $0.3421
Daily change: -$0.0632 (-15.59%)
Daily volume: 2.7M
Industry: Biotechnology
This is a signal that FGEN's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position. A.I.dvisor identified 61 similar cases where FGEN's stochastic oscillator exited the overbought zone, and of them led to successful outcomes. Odds of Success:

FGEN in -4.97% downward trend, sliding for three consecutive days on December 16, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where FGEN declined for three days, in of 315 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 06, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on FGEN as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FGEN turned negative on December 06, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

FGEN moved below its 50-day moving average on December 11, 2024 date and that indicates a change from an upward trend to a downward trend.

FGEN broke above its upper Bollinger Band on November 11, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for FGEN crossed bullishly above the 50-day moving average on November 25, 2024. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FGEN advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. FGEN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). FGEN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.192) is also within normal values, averaging (260.687).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
FGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biotechnology-based drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
409 Illinois Street
Phone
+1 415 978-1200
Employees
486
Web
https://www.fibrogen.com